Colorectal Cancer Payment Fairness Act
- Sponsor
- Rep. Watson Coleman, Bonnie [D-NJ-12]
- Committees
- Ways and Means Committee (primary)
- Last action
- Sep 30, 2025
Bottom line
This bill ensures Medicare beneficiaries will not pay any out-of-pocket coinsurance for colorectal cancer screening tests, aiming to improve access and early detection.
What it actually does
This bill amends the Social Security Act to permanently eliminate the coinsurance requirement for certain colorectal cancer screening tests under the Medicare program. It removes a previous sunset date of January 1, 2030, and mandates that for 2027 and all subsequent years, Medicare will cover 100% of the cost of these screening tests, meaning beneficiaries will pay no out-of-pocket coinsurance.
Proponents argue
Supporters argue that eliminating coinsurance removes a significant financial barrier that can deter Medicare beneficiaries from undergoing crucial colorectal cancer screenings. They contend that increased screening rates will lead to earlier detection, better treatment outcomes, and ultimately save lives and reduce long-term healthcare costs associated with advanced cancer treatments.
Opponents contend
Potential opponents might argue that while the goal is laudable, eliminating coinsurance for all screening tests could increase Medicare expenditures, potentially contributing to the program's long-term financial challenges. They might also suggest that a small coinsurance helps to ensure judicious use of healthcare services, though this argument is less common for preventive screenings.
The bill text is extremely short and can be read in under a minute, making it highly accessible for public review.
Section 2
Elimination of Coinsurance for Colorectal Cancer Screening Tests
This section amends the Social Security Act to permanently remove the coinsurance requirement for certain colorectal cancer screening tests covered by Medicare. Specifically, it strikes the previous expiration date of January 1, 2030, and mandates that for 2027 and all subsequent years, Medicare will cover 100% of the cost of these screening tests, meaning beneficiaries will pay no coinsurance.
Supporters argue
Supporters argue that removing financial barriers is critical for increasing screening rates, especially among vulnerable populations, leading to earlier detection of colorectal cancer when it is most treatable. This aligns with public health goals to reduce cancer mortality.
Critics contend
Critics might express concern that while beneficial for individuals, the increased cost burden on the Medicare program could exacerbate its financial sustainability challenges without a clear offset. They might question the long-term fiscal implications of expanding 100% coverage for all such screenings.
Tradeoffs
The bill balances the public health benefit of increased cancer screening and early detection against the potential for increased federal healthcare expenditures. It also addresses the tension between individual out-of-pocket costs and the overall financial health of the Medicare system.